Evidence map›Paper›PMID 28440466›Full record

ArticleOncology reports2017

miR-200a targets Gelsolin: A novel mechanism regulating secretion of microvesicles in hepatocellular carcinoma cells.

Ya Xu, Yanfen Zhang, Lujing Wang, Ruiqi Zhao, Yu Qiao, Dong Han, Qian Sun, Nazhen Dong, Yicong Liu, Dantong Wu and 6 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 28 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 1 country.

Ya XuDepartment of Biochemistry and Molecular Biology, Harbin Medical University, Harbin, Heilongjiang, P.R. China.
Yanfen ZhangDepartment of Laboratory Diagnosis, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, P.R. China.
Lujing WangDepartment of Biochemistry and Molecular Biology, Harbin Medical University, Harbin, Heilongjiang, P.R. China.
Ruiqi ZhaoDepartment of Biochemistry and Molecular Biology, Harbin Medical University, Harbin, Heilongjiang, P.R. China.
Yu QiaoDepartment of Biochemistry and Molecular Biology, Harbin Medical University, Harbin, Heilongjiang, P.R. China.
Dong HanDepartment of Biochemistry and Molecular Biology, Harbin Medical University, Harbin, Heilongjiang, P.R. China.
Qian SunDepartment of Biochemistry and Molecular Biology, Harbin Medical University, Harbin, Heilongjiang, P.R. China.
Nazhen DongDepartment of Biochemistry and Molecular Biology, Harbin Medical University, Harbin, Heilongjiang, P.R. China.
Yicong LiuDepartment of Biochemistry and Molecular Biology, Harbin Medical University, Harbin, Heilongjiang, P.R. China.
Dantong WuDepartment of Biochemistry and Molecular Biology, Harbin Medical University, Harbin, Heilongjiang, P.R. China.
Xuemei ZhangDepartment of Biochemistry and Molecular Biology, Harbin Medical University, Harbin, Heilongjiang, P.R. China.
Ning HuangDepartment of Biochemistry and Molecular Biology, Harbin Medical University, Harbin, Heilongjiang, P.R. China.
Ning MaDepartment of Biochemistry and Molecular Biology, Harbin Medical University, Harbin, Heilongjiang, P.R. China.
Weiming ZhaoDepartment of Biochemistry and Molecular Biology, Harbin Medical University, Harbin, Heilongjiang, P.R. China.
Yanhong LiuDepartment of Laboratory Diagnosis, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, P.R. China.
Xu GaoDepartment of Biochemistry and Molecular Biology, Harbin Medical University, Harbin, Heilongjiang, P.R. China.
Harbin Medical University · CNSecond Affiliated Hospital of Harbin Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Microvesicle biogenesis is a highly regulated process. Aberrant release of microvesicles from cancer cells have been associated with their invasiveness and prognosis. However, the mechanism of aberrant release remains poorly understood. Herein, we found that hepatocellular carcinoma cells shed more microvesicles than normal hepatocytes and miR-200a were shown to inhibit the release of microvesicles in hepatocellular carcinoma cells. Then, we confirmed that miR-200a might target Gelsolin and change cytoskeleton to regulate microvesicles secretion. Further miR-200a may inhibit the proliferation of adjacent cells by inhibiting the release of microvesicles. Collectively, our findings indicate that miR-200a regulated the microvesicle biogenesis involved in the hepatocellular carcinoma progression.

Indexed as

Carcinoma, HepatocellularCell-Derived MicroparticlesCell Line, TumorCell MovementCell ProliferationDisease ProgressionGelsolinGene Expression Regulation, NeoplasticHep G2 CellsHumansLiver NeoplasmsMicroRNAsPrognosisGelsolinMicroRNAsMIRN200 microRNA, human

Identifiers

PMID28440466
PMCPMC5428402
OpenAlexW2601040185

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.